To report the final data of a Phase I and II study (1839IL/0092) on the combination of an anti-epidermal growth factor receptor drug (gefitinib), infusional 5-fluorouracil, and preoperative radiotherapy in locally advanced, resectable rectal cancer.
Valentini, V., De Paoli, A., Gambacorta, M. A., Mantini, G., Ratto, C., Vecchio, F. M., Barbaro, B., Innocente, R., Rossi, C., Boz, G., Barba, M. C., Frattegiani, A., Lupattelli, M., Doglietto, G., Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092), <<INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS>>, 2008; 72 (3): 644-649. [doi:10.1016/j.ijrobp.2008.01.046] [http://hdl.handle.net/10807/32968]
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092)
Valentini, Vincenzo;Gambacorta, Maria Antonietta;Mantini, Giovanna;Ratto, Carlo;Vecchio, Fabio Maria;Barbaro, Brunella;Rossi, Concettina;Barba, Maria Cristina;Frattegiani, Alessandro;Doglietto, Giovanni
2008
Abstract
To report the final data of a Phase I and II study (1839IL/0092) on the combination of an anti-epidermal growth factor receptor drug (gefitinib), infusional 5-fluorouracil, and preoperative radiotherapy in locally advanced, resectable rectal cancer.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
